On the stock market since 2002, it operates in the world of health and science. It has 3,200 employees. Now — the numbers.
This is an established company with proven profits.
Average growth of 5% a year over the last 4 years. Red columns mark years that ended in a loss.
The gap is $141.9M. In times of high interest rates, a gap like that can squeeze a company.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
Clearly below the class average.
Clearly above the class average — a step short of the very top.
This grade is a blend: the profit side is strong, the sales tempo slow.
Clearly above the class average — a step short of the very top.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
The stock trades 30% below its peak. The market has trimmed its expectations for the company.
Nothing in the current numbers stands out as a strong positive. That, by itself, is worth knowing.
Over the last 3 years, sales grew only 2% a year on average — the report card’s higher growth grade leans on profit power instead.
The company’s market value is 90 times its annual profit. Even a small disappointment could hit the price hard.
On our five-subject report card, TBRG sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: TBRG is an established business that has proven its profits for years. The real debate here isn’t the price — it’s whether the company can keep up this pace.